Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03358147 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,077
- Enrollment target
NCT03358147 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 1,077 participants.
The verdict
NCT03358147, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,077 participants
- Enrollment target
Study Summary
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
Interventions
- DRUG Placebo MDI
- DRUG GP MDI 28.8 μg
- DRUG GP MDI 14.4 μg
- DRUG GP MDI 7.2 μg
- DRUG Spiriva Respimat 2.5 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,077 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2019-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03358147
The ClinicalTrials.gov registry entry for NCT03358147 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,077 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo MDI is the first listed.
NCT03358147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03358147 about?
NCT03358147 is a clinical study titled "Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma". Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
What is the current status of trial NCT03358147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,077 participants. The study started on 2017-12-13. Estimated completion is 2019-09-12.
What interventions are being tested in trial NCT03358147?
The interventions under investigation include: Placebo MDI (DRUG), GP MDI 28.8 μg (DRUG), GP MDI 14.4 μg (DRUG), GP MDI 7.2 μg (DRUG), Spiriva Respimat 2.5 μg (DRUG).
Who is sponsoring clinical trial NCT03358147?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.